• Voting Rights and Shares Capital of the Company

    Source: Nasdaq GlobeNewswire / 08 Jun 2023 16:15:00   America/New_York

    In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers)

    PARIS, June 08, 2023 (GLOBE NEWSWIRE) --
    Market: Euronext Paris / Nasdaq
    Euronext Compartment: B
    ISIN code: FR0011341205
    Nasdaq: NBTX
    Bloomberg: NANO:FP
    Reuters: NANO.PA
    Website: www.nanobiotix.com

    Date
    		Number of Shares
    Outstanding
    		Total number of voting rights
    Total voting rights, theoretical1

    		Total voting rights,
    exercisable2
    May 31, 2023

    		34,875,87236,622,30936,600,191

    According to the article L.233-8 II of the French Commercial Code, Nanobiotix will make a new monthly publication of the total number of voting rights and shares comprising Nanobiotix’s capital if those figures differ from the information previously disclosed.

    About NANOBIOTIX

    Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The company is leveraging its proprietary nanoparticle platform, including its lead product candidate, radiotherapy activated NBTXR3, to develop a pipeline of therapeutic options designed to enhance local and systemic control of solid tumors with an initial focus on the treatment of head and neck cancers. 

    For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter. 

    Contacts

    Nanobiotix

    Nanobiotix Communications
    Brandon Owens
    VP, Communications
    +1 (617) 852-4835
    contact@nanobiotix.com


    Nanobiotix Investor Relations
    Craig West
    SVP, Investor Relations
    +1 (617) 583-0211 
    investors@nanobiotix.com

    Media Relations


    France – Ulysse Communication
    Pierre-Louis Germain
    + 33 (0) 6 64 79 97 51
    plgermain@ulysse-communication.com

    LifeSci Advisors 
    Ligia Vela-Reid 
    +44 (0) 7413825310 
    lvela-reid@lifesciadvisors.com

     

    1 The total number of theoretical (or “gross”) voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

    2 The total number of exercisable at a Shareholders’ Meeting (or “net”) voting rights is calculated without taking into account shares for which voting rights have been suspended as shares held in treasury by the Company. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007. 

    Attachment


Share on,